MX2012014321A - Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. - Google Patents
Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.Info
- Publication number
- MX2012014321A MX2012014321A MX2012014321A MX2012014321A MX2012014321A MX 2012014321 A MX2012014321 A MX 2012014321A MX 2012014321 A MX2012014321 A MX 2012014321A MX 2012014321 A MX2012014321 A MX 2012014321A MX 2012014321 A MX2012014321 A MX 2012014321A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- reductive amination
- pharmaceutically acceptable
- ivabradine
- acceptable acid
- Prior art date
Links
- 229960003825 ivabradine Drugs 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 title claims abstract description 10
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 title claims abstract 3
- 239000002253 acid Substances 0.000 title abstract description 6
- 150000003839 salts Chemical class 0.000 title abstract description 5
- 230000002194 synthesizing effect Effects 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 15
- 238000006268 reductive amination reaction Methods 0.000 claims description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000004677 hydrates Chemical class 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- HLUKNZUABFFNQS-ZMBIFBSDSA-N ivabradine hydrochloride Chemical compound Cl.C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 HLUKNZUABFFNQS-ZMBIFBSDSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000010970 precious metal Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- 238000005847 Wailach reaction Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960000504 ivabradine hydrochloride Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1103934A FR2984320B1 (fr) | 2011-12-20 | 2011-12-20 | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012014321A true MX2012014321A (es) | 2013-06-19 |
Family
ID=47355960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012014321A MX2012014321A (es) | 2011-12-20 | 2012-12-07 | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8507668B2 (ro) |
| EP (1) | EP2607354B1 (ro) |
| JP (1) | JP5531084B2 (ro) |
| KR (1) | KR101479986B1 (ro) |
| CN (1) | CN103172567B (ro) |
| AR (1) | AR089325A1 (ro) |
| AU (1) | AU2012261583B2 (ro) |
| BR (1) | BR102012032562A2 (ro) |
| CA (1) | CA2798633C (ro) |
| CL (1) | CL2012003579A1 (ro) |
| CY (1) | CY1115620T1 (ro) |
| DK (1) | DK2607354T3 (ro) |
| EA (1) | EA021713B1 (ro) |
| ES (1) | ES2516290T3 (ro) |
| FR (1) | FR2984320B1 (ro) |
| GE (1) | GEP20156245B (ro) |
| HR (1) | HRP20140839T1 (ro) |
| JO (1) | JO3083B1 (ro) |
| MA (1) | MA34868B1 (ro) |
| MD (1) | MD4275C1 (ro) |
| MX (1) | MX2012014321A (ro) |
| MY (1) | MY160928A (ro) |
| PE (1) | PE20131325A1 (ro) |
| PL (1) | PL2607354T3 (ro) |
| PT (1) | PT2607354E (ro) |
| RS (1) | RS53470B (ro) |
| SA (1) | SA112340106B1 (ro) |
| SG (1) | SG191498A1 (ro) |
| SI (1) | SI2607354T1 (ro) |
| TW (1) | TWI440628B (ro) |
| UA (1) | UA111156C2 (ro) |
| UY (1) | UY34508A (ro) |
| WO (1) | WO2013093333A1 (ro) |
| ZA (1) | ZA201209369B (ro) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2988720B1 (fr) * | 2012-03-27 | 2014-03-14 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2681862B1 (fr) * | 1991-09-27 | 1993-11-12 | Adir Cie | Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent. |
| FR2868777B1 (fr) * | 2004-04-13 | 2006-05-26 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868775B1 (fr) * | 2004-04-13 | 2008-04-11 | Servier Lab | Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2868776B1 (fr) * | 2004-04-13 | 2008-04-18 | Servier Lab | Nouveau procede de synthese de derives de la 1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2870537A1 (fr) * | 2004-05-19 | 2005-11-25 | Servier Lab | Nouveau procede de synthese du (1s)-4,5-dimethoxy-1-(methyl aminomethyl-)-benzocyclobutane et de ses sels d'addition, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| RU2473544C2 (ru) * | 2007-05-30 | 2013-01-27 | Инд-Свифт Лабораториз Лимитед | Способ получения ивабрадина гидрохлорида и его полиморфных модификаций |
| FR2920773B1 (fr) * | 2007-09-11 | 2009-10-23 | Servier Lab | Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2932800B1 (fr) * | 2008-06-20 | 2015-02-20 | Servier Lab | Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| FR2935381B1 (fr) * | 2008-08-29 | 2010-12-17 | Servier Lab | Nouveau procede de resolution des enantiomerees du (3,4-dimethoxy-bicyclo°4.2.0!octa-1,3,5-trien-7-yl)nitrile et application a la synthese de l'ivabradine |
| FR2940287B1 (fr) * | 2008-12-24 | 2010-12-24 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| FR2941695B1 (fr) * | 2009-02-04 | 2011-02-18 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable |
| WO2010096416A1 (en) * | 2009-02-17 | 2010-08-26 | Mallinckrodt Inc. | Process for the reductive alkylation of normorphinans |
| FR2943668B1 (fr) * | 2009-03-31 | 2011-05-06 | Servier Lab | Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
-
2011
- 2011-12-20 FR FR1103934A patent/FR2984320B1/fr not_active Expired - Fee Related
-
2012
- 2012-12-04 SG SG2012089041A patent/SG191498A1/en unknown
- 2012-12-05 PE PE2012002275A patent/PE20131325A1/es active IP Right Grant
- 2012-12-06 JO JOP/2012/0370A patent/JO3083B1/ar active
- 2012-12-07 MX MX2012014321A patent/MX2012014321A/es active IP Right Grant
- 2012-12-07 AU AU2012261583A patent/AU2012261583B2/en not_active Ceased
- 2012-12-07 MY MYPI2012701116A patent/MY160928A/en unknown
- 2012-12-11 UY UY0001034508A patent/UY34508A/es unknown
- 2012-12-11 CA CA2798633A patent/CA2798633C/fr not_active Expired - Fee Related
- 2012-12-11 ZA ZA2012/09369A patent/ZA201209369B/en unknown
- 2012-12-14 US US13/714,950 patent/US8507668B2/en not_active Expired - Fee Related
- 2012-12-14 MD MDA20120123A patent/MD4275C1/ro not_active IP Right Cessation
- 2012-12-18 KR KR20120148761A patent/KR101479986B1/ko not_active Expired - Fee Related
- 2012-12-18 GE GEAP201212929A patent/GEP20156245B/en unknown
- 2012-12-18 SA SA112340106A patent/SA112340106B1/ar unknown
- 2012-12-18 UA UAA201214527A patent/UA111156C2/uk unknown
- 2012-12-19 CN CN201210554758.0A patent/CN103172567B/zh not_active Expired - Fee Related
- 2012-12-19 BR BR102012032562-4A patent/BR102012032562A2/pt not_active Application Discontinuation
- 2012-12-19 RS RS20140425A patent/RS53470B/sr unknown
- 2012-12-19 EA EA201201571A patent/EA021713B1/ru not_active IP Right Cessation
- 2012-12-19 ES ES12197929.8T patent/ES2516290T3/es active Active
- 2012-12-19 TW TW101148518A patent/TWI440628B/zh not_active IP Right Cessation
- 2012-12-19 PL PL12197929T patent/PL2607354T3/pl unknown
- 2012-12-19 SI SI201230075T patent/SI2607354T1/sl unknown
- 2012-12-19 AR ARP120104818A patent/AR089325A1/es unknown
- 2012-12-19 CL CL2012003579A patent/CL2012003579A1/es unknown
- 2012-12-19 PT PT121979298T patent/PT2607354E/pt unknown
- 2012-12-19 MA MA35475A patent/MA34868B1/fr unknown
- 2012-12-19 JP JP2012276524A patent/JP5531084B2/ja active Active
- 2012-12-19 EP EP12197929.8A patent/EP2607354B1/fr active Active
- 2012-12-19 WO PCT/FR2012/052982 patent/WO2013093333A1/fr not_active Ceased
- 2012-12-19 DK DK12197929.8T patent/DK2607354T3/da active
-
2014
- 2014-09-04 HR HRP20140839AT patent/HRP20140839T1/hr unknown
- 2014-10-14 CY CY20141100833T patent/CY1115620T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4148952B2 (ja) | （１ｓ）−４，５−ジメトキシ−１−（メチルアミノメチル）ベンゾシクロブタン及びその付加塩合成の新規な方法、並びにイバブラジン、及び薬学的に許容され得る酸とのその付加塩の合成への適用 | |
| CN101735140A (zh) | 手性胺基化合物、合成方法及其抗流感药物达菲中间体的用途 | |
| JP4515933B2 (ja) | １，３，４，５−テトラヒドロ−２ｈ−３−ベンゾアゼピン−２−オン化合物の新規な合成方法、並びにイバブラジン及び薬学的に許容され得る酸とのその付加塩の合成への適用 | |
| EP2487158B1 (fr) | Nouveau procédé de synthèse de l'ivabradine et de ses sels d'addition à un acide pharmaceutiquement acceptable | |
| MX2012014321A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| TWI440627B (zh) | 合成依伐布雷定（ｉｖａｂｒａｄｉｎｅ）及其與醫藥上可接受酸之加成鹽之新穎方法 | |
| HK1186734B (en) | A process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| NZ604890B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| CN111393309B (zh) | 一种(s)-1,2,3,4-四氢-5-甲氧基-n-丙基-2-萘胺盐酸盐制备方法 | |
| CN111018734A (zh) | 一种盐酸西那卡塞中间体的合成方法 | |
| HK1186733B (en) | New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |